However, FAK7/FAK6,7-expressing cells presented reduced sensitivity to the mTOR inhibitor (Supplementary Fig. 11g), suggesting that SCLC cells with FAK variants may survive mTOR inhibition, possibly through increased activity of the AKT and Bcl-2/Myc pathways. The gene discussed is AKT1; the disease is small cell lung carcinoma.